109 related articles for article (PubMed ID: 12848732)
1. Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.
Jones RN; Anderegg TR; Biedenbach DJ
Clin Microbiol Infect; 2003 Jun; 9(6):543-6. PubMed ID: 12848732
[TBL] [Abstract][Full Text] [Related]
2. Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
Anderegg TR; Jones RN
Int J Antimicrob Agents; 2004 Jan; 23(1):6-10. PubMed ID: 14732307
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
J Antimicrob Chemother; 2002 Aug; 50(2):271-6. PubMed ID: 12161411
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
[TBL] [Abstract][Full Text] [Related]
5. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Mutnick AH; Enne V; Jones RN
Ann Pharmacother; 2003 Jun; 37(6):769-74. PubMed ID: 12773059
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
Anderegg TR; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 2002 Aug; 46(8):2662-4. PubMed ID: 12121951
[TBL] [Abstract][Full Text] [Related]
7. Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.
Jones RN; Holliday NM; Rhomberg PR
J Clin Microbiol; 2015 Feb; 53(2):657-9. PubMed ID: 25411167
[TBL] [Abstract][Full Text] [Related]
8. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
9. A multicenter evaluation of linezolid antimicrobial activity in North America.
Ballow CH; Jones RN; Biedenbach DJ;
Diagn Microbiol Infect Dis; 2002 May; 43(1):75-83. PubMed ID: 12052632
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
Jones RN; Biedenbach DJ; Anderegg TR
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):119-22. PubMed ID: 11858907
[TBL] [Abstract][Full Text] [Related]
11. Linezolid activity against clinical Gram-positive cocci with advanced antimicrobial drug resistance in Iran.
Houri H; Kazemian H; Sedigh Ebrahim-Saraie H; Taji A; Tayebi Z; Heidari H
J Glob Antimicrob Resist; 2017 Sep; 10():200-203. PubMed ID: 28735054
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels.
Ross JE; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):219-21. PubMed ID: 15766610
[TBL] [Abstract][Full Text] [Related]
13. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
Jones RN; Anderegg TR; Deshpande LM
Diagn Microbiol Infect Dis; 2002 May; 43(1):87-90. PubMed ID: 12052634
[TBL] [Abstract][Full Text] [Related]
14. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.
Peric M; Lin G; Clark CL; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):95-100. PubMed ID: 12096012
[TBL] [Abstract][Full Text] [Related]
15. Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.
Anderegg TR; Jones RN;
Diagn Microbiol Infect Dis; 2003 Jan; 45(1):73-6. PubMed ID: 12573554
[TBL] [Abstract][Full Text] [Related]
16. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.
Jones RN; Streit JM; Fritsche TR
Int J Antimicrob Agents; 2004 Feb; 23(2):197-9. PubMed ID: 15013046
[TBL] [Abstract][Full Text] [Related]
17. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
[TBL] [Abstract][Full Text] [Related]
18. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
Fritsche TR; Moet GJ; Jones RN
Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
[TBL] [Abstract][Full Text] [Related]
19. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
Ednie LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):101-5. PubMed ID: 12096013
[TBL] [Abstract][Full Text] [Related]
20. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
